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Abstract
Brain metastases (BMs) are the leading cause of cancer-related deaths,
comprise the majority of central nervous system malignancies, and widely
originate from non-small lung carcinomas (NSCLC). Immunotherapy, particularly
checkpoint inhibitors, has emerged as the standard of care for most patients with
advanced lung cancer. Pannexin1 (PANX1) is a transmembrane glycoprotein
that forms large-pore channels and has been reported to promote tumorigenesis
in metastatic cancers. The roles of PANX1 in lung cancer-associated brain
metastases and tumor-infiltrating lymphocytes have not been identified. Forty-two
patient-matched formalin-fixed paraffin-embedded tissue samples from lung
carcinomas and subsequent brain metastases were constructed into two mastertissue microarrays (TMAs). PANX1, PD-L1, and tumor-infiltrating immune cells
(CD3+, CD4+, CD8+, and CD68+) were assessed using immunohistochemistry
and digital image analysis (QuPath software). The expression of PANX1 was
significantly higher in brain metastases than paired primary lung carcinoma.
Strikingly, the level of PANX1 in lung carcinoma cells in the brain correlated
negatively with the infiltration density of blood-derived macrophages. Our findings
highlight the role of PANX1 in the progression of metastatic NSCLC, and the
potential therapeutic approach of targeting PANX1 enhances the efficacy of
immune checkpoint inhibitors in brain metastasis.
Keywords: Pannexins, Pannexin1, Lung cancer, Non-small cell lung carcinoma,
Brain metastases, Tumor-immune infiltration, Tumor-associated macrophages.
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Summary for Lay Audience

Cancer from other parts of the body can spread to the brain. This is known as
brain metastasis, the leading cause of cancer-related deaths. Brain metastases
comprise the majority of brain tumors and widely originate from lung cancer.
Immunotherapy approaches have emerged as the standard of care for most
patients with advanced lung cancer. However, the difference in brain metastasis
progress and response to immunotherapies among lung cancer patients requires
robustly predictive- cellular parameters. Pannexin1 (PANX1) is a cellular protein
that forms large-pore channels and has been reported to promote
aggressiveness in multiple cancers. The roles of PANX1 in brain metastasis and
immune responses have not been identified. Therefore, we studied 42 patient
specimens obtained from lung cancers and their migratory cells in the brain and
eventually conducted biological staining to assess the profiles of PANX1 and
immune cells within cancer compartments. We found that PANX1 was higher in
brain metastases compared to primary lung cancer. Immune cells known as
macrophages that digest harmful structures and/or present them to T cells
(cancer cells’ killers) were less in brain metastasis cases with high levels of
PANX1. These findings indicate the role of PANX1 in cancer progression and the
immunological profile of advanced lung cancer.
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Section 1: Introduction
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1.1 Non-small cell lung carcinoma (NSCLC)
Lung cancer leads to the largest number of cancer-related deaths worldwide1.
It is classified into two main histological groups: small cell lung carcinoma
(SCLC, 15% of all lung cancers) and non-SCLC (NSCLC, 85% of all lung
cancers). NSCLCs are generally subcategorized into adenocarcinoma (ADC,
~50%), squamous cell carcinoma (SCC,~40%), and large cell carcinoma
(~10%)2. In general, ADCs arise in more distal airways, whereas SCCs arise in
more proximal airways and are more associated with smoking and chronic
inflammation than ADCs3,4. ADCs often have glandular histology and express
persistent biomarkers with an origin in the distal lung, including thyroid
transcription factor 1 (TTF1; also known as NKX2-1) and keratin 7 (KRT7)3,4.
However, SCCs are characterized by squamous differentiation and
distinguished from ADCs in the clinic by immunostaining for cytokeratin 5 and
cytokeratin 6 and/or the transcription factors SRY-box 2 (SOX2) and p633–5.
Large cell carcinoma is diagnosed with exclusion if tumor cells do not have
glandular or squamous morphology or express ADC or SCC biomarkers3.
Epidermal growth factor receptor (EGFR) and K-RAS mutations are the most
prevalent- identified drivers of NSCLC in East Asia, Caucasian cohort, and
Vietnamese cohorts6. Advances in next-generation sequencing (NGS) and
other genomic profiling platforms have allowed researchers to examine the
latitude of genetic mutations within lung tumors. After identifying KRAS and
BRAF mutations7,8, epidermal growth factor receptor (EGFR) mutations were
discovered in patients with lung ADC and were associated with response to
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EGFR inhibitors9–12. In a recent study13, 256-Chinese patients with NSCLC
were enrolled. NGS-based genomic profiling of central lung cancer-related
genes was performed on a formalin-fixed paraffin-embedded tumor sample and
found higher frequencies of anaplastic lymphoma kinase (ALK) and BRAF
alterations were associated with younger age. The frequency of mutations in
EGFR was significantly higher in nonsmokers than in smokers13. It has been
revealed that β-catenin is essential for the development of EGFR-mutated lung
cancers14. Pharmacologic inhibition of β-catenin suppressed EGFR-mutated
lung tumor growth, and genetic deletion of the β-catenin gene dramatically
reduced lung tumor formation in mutated-EGFR transgenic mice14. Therefore,
β-catenin is critical for lung carcinoma progression.

1.2 Brain metastases
An estimated 20% of cancer patients develop brain metastases (BMs) 15;
however, autopsy studies have suggested higher incidences (up to 40%) of
intracranial metastases in patients with tumors 16. While any tumor can
metastasize to the brain, the three most prevalent primary tumors associated
with brain metastases are lung (40–56% of patients), breast (5–20%), and
melanoma (7–16%)17–19. Lung cancer is the most predominant to metastasize
to the brain regardless of patient sex and is the most common brain metastasis
in men, whereas breast cancer is the most commonly occurring brain
metastasis in women15. The molecular phenotype of the primary tumor could
influence the risk of developing brain metastases. For instance, women with
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breast cancers characterized by human epidermal growth factor receptor 2
(ERBB2, also known as HER2) amplification or triple-negative hormone
receptor status (that is, estrogen receptor (ER)-negative, progesterone
receptor (PR)-negative and normal HER2 levels) have a higher risk of
developing brain metastases than those with ER-positive and/or PR-positive
breast cancer20. Likewise, ALK-rearranged NSCLC has a higher tendency to
metastasize to the brain. Advanced primary cancer disease also influences the
risk of progressing brain metastasis21 and intensifies the likelihood of its
emergence22; however, the time interval from initial cancer diagnosis to the
development of brain metastases is highly influenced by the primary cancer
type23. In a study, the time interval for patients with breast cancer to develop
brain metastases was 44 months, whereas it was 11 months for lung cancer 17.
Other contributing factors to the development of brain metastases entail
ethnicity, age, and geographic location. A study demonstrated that African
Americans with lung cancer, melanoma, and breast cancer had a higher
incidence of brain metastases than other ethnic groups with the same cancer
types24. In contrast, renal cell carcinoma (RCC)-brain metastases in African
Americans were lower than in white patients. The risk of brain metastases also
differs with age regardless of the tumor phenotype24,25. For example, in one
study, the risk of breast cancer brain metastases was highest in younger
patients (20–39 years of age), but the risk of lung cancer brain metastases was
highest in middle age (40–49 years of age); melanoma, RCC and colorectal
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cancer (CRC) - brain metastases arose with the highest risk a decade later
(50–59 years of age).
Brain metastases develop upon disseminating cells from a primary tumor through
the blood to the brain microvasculature despite potential occurrence from
established metastases. As illustrated in (Figure 1), tumor cells initially detach
from the primary tumor, acquire stem cell-like properties, resulting in an
epithelial-mesenchymal transition, and invade the surrounding tissues, venules,
capillaries, and lymphatic system91. Tumor cell interactions with immune cells
promote cell motility via clearance of extracellular matrix. In the circulation, tumor
cells undergo adhesive-circulatory arrest within the vasculature and extravasate,
either as single cells or emboli. The abundance of capillary networks in the brain
and high blood flow causes a high exposure to circulating tumor cells. A
circulatory arrest is enhanced by slowed movement at branch points in capillaries
(~3–7 μm in diameter), as well as the larger size of tumor cells (up to 20 μm)
compared with deformable red blood cells (7 μm)28,29. Tumor cells permeate the
disruptive brain functional barriers, blood-brain barrier (BBB)30, and bloodcerebrospinal fluid (CSF) barrier31. Brain metastases tend to occur at the junction
between grey and white matter and watershed areas between vascular
territories, where it is proposed that circulating tumor cells benefit from longer
relative mean transit times of blood flow, enabling more time for the cells to
overcome the blood-brain barrier and exit from the vasculature15. After arresting
and extravasating, most tumor cells die rather than form metastases, whereas
others can lie dormant at metastatic sites for extended periods32. Tumor cell
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interplays with the brain microenvironment lead to the outgrowth of tumor cells
and cancer-specific signaling pathways19. Metastases are environed by a
neuroinflammatory response33, including activated astrocytes, microglia, and
immune cells, which will be discussed in the following section.
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Figure 1. Cancer cell metastatic dissemination to the brain. Brain
metastases develop after the hematogenous spread of cells from a primary lung
tumor to the brain microvasculature, with subsequent tumor growth enhanced by
microenvironmental niche–tumor interactions. Initially, tumor cells escape
primary bulk tumors and invade the surrounding tissues. Once in the circulation,
circulating tumor cells establish the process of metastatic extravasation from the
vasculature. After extravasating, most tumor cells die rather than form
metastases, whereas others can lie dormant at metastatic sites for extended
periods. The figure was drawn on BioRender and modified from Achrol et al. 15.
The green color indicates lung carcinoma cells, whereas the brown refers to
stromal cells.
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1.3 Genomic profiles of brain metastases derived from NSCLC
Brain metastases are diagnosed in more than a quarter of patients with stage IV
NSCLC34. Approximately 10–21% of lung tumors are initially diagnosed with
brain metastasis, and 50–60% will develop into brain metastases during the
course of the disease35. While a role of PD-1, LKB1, KRAS, and EGFR mutations
and ALK rearrangements has been associated with the progression of lung
cancer36,37, their presumptive pathogenesis of brain metastases is still
debatable37,38. Detailed genomic profiling of primary NSCLC and matched brain
metastases was performed with next-generation sequencing targeting 416
cancer-relevant genes on 61 patients who had surgical resection of primary
NSCLC and brain metastases39. In this study, mutations of major drivers,
including EGFR, KRAS, TP53, and ALK, were highly universal between primary
NSCLC and matched brain metastases (>80%), while discordance suggested the
exclusive oncogenic mechanisms of NSCLC brain metastases. Altered cell cycle
regulators and PI3K pathway were more enriched in brain metastases, and
activated PI3K signaling correlates with shorter survival39. In the study of Villalva
et al.40, molecular alterations of KRAS, EGFR, and ALK were present in 39%,
3.9%, and 7.7% of brain metastases, respectively. The concordance percentage
of the EGFR mutations in paired primary NSCLCs and brain metastases ranges
between 36% and 100%41–44. Therefore, testing EGFR mutations in the primary
site of NSCLC may not be informative for using EGFR tyrosine kinase inhibitors
(TKIs) to treat brain metastases. However, a significant bulk of NSCLCs has no
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molecular alterations; therefore, there is a need to investigate other potential
targetable biomarkers.
1.4 The immune microenvironment in brain metastases
Intercommunication between tumor cells and cellular members of the
microenvironment sustains normal tissue homeostasis and supports tumor
growth. This intercellular communication is operated by a dynamic network of
cytokines, chemokines, growth factors, and enzymes remodeling the extracellular
matrix, leading to profound changes in properties of the surrounding tissue 45,46.
The brain was previously considered an immunologically privileged organ
because the healthy brain has almost no lymphocytes46. However, the central
nervous system is a specialized immune site under a regulatory network linking
native brain cells and lymphocytes47. In established brain metastases, the
inflammatory tumor microenvironment comprises the innate immune system,
microglia, blood-derived myeloid cells/macrophages, and the adaptive immune
system, essentially represented by T cells48. Microglia are the critical cells of the
innate immune system in the brain. Physiologically, microglia are motile and
constantly move through the brain parenchyma49. Therefore, microglia cells
reside heterogeneously within the healthy brain 50. The differences in microglia
distribution were observed early during the process of extravasation in brain
metastasis preclinical models, indicating that microglia may be involved in
extravasation and survival in the perivascular niche33. Microglia functions in brain
metastasis encompass antigen presentation, cytotoxicity via expression of nitric
oxide (NO) and superoxide, and phagocytosis49. A crucial function of microglial
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cells in brain metastasis is T-cell activation upon expression of the HLA
ABC/major histocompatibility antigen class I. Therefore, microglial activation is
essential for inducing a specific immune response, including T and B cells 49.
PD-L1 expression, the ligand of the inhibitory T-cell co-receptor PD1, is
expressed on microglia cells and can suppress T-cells51. Microglia with
phagocytic activities is a member of the tumor-association macrophages (TAMs)
population within brain metastasis, including blood-derived macrophages33. Two
functional phenotypes of TAMs have been proposed. The M1 TAMs are defined
by tumor-suppressive functions like inhibition of cell proliferation52. The M2 TAMs
have tumor-promoting functions, including suppressing the adaptive immune
response and promoting tumor cell migration, invasion, and intravasation into the
vascular system, angiogenesis, and persistent growth52. There was previously no
specific biomarker to differentiate resident microglia and bone marrow-derived
macrophages BMDMs53. CD49D and TMEM 119 have recently been identified as
differential markers between BMDMs and microglia53,54. These studies also
proposed that most TAMs in the brain metastases were derived from peripheral
monocytes and not from resident microglia.
Lymphocytes generally are not present in the brain parenchyma and migrate into
the CNS under pathological condition55. Several subtypes of tumor-infiltrating
lymphocytes (TILs) can be found in the brain metastasis ' inflammatory
microenvironment and vary in physiology and prognostic significance56. CD3+
TILs represent the overall population of effector T cells. CD8+ TILs represent
cytotoxic T-cell, whereas CD4+ TILs reflect helper T cells. FOXP3+/CD25+/CD4+
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TILs are called regulator T cells and have immunosuppressive function57. They
inhibit the function of CD8+ cytotoxic T-cell and contribute to an immune
suppressive microenvironment. Characteristics of the primary tumor can
influence the T cell response in brain metastases. A denser TIL infiltration was
observed in brain metastases derived from melanoma and RCC compared with
those derived from breast cancer and non-small lung carcinoma58. Brain
metastases’ patients with dense infiltration of effector CD3+ or cytotoxic CD8+
had an improved survival prognosis from diagnosis compared with patients with
absent or fewer infiltration of TILs57. The immune response is physiologically
counterbalanced by inhibitory pathways, which prevent uncontrolled immune
response; these inhibitory pathways are immune checkpoints that maintain the
immune homeostasis59,60. In cancer, tumor cells typically express immune
checkpoints to halt the antitumor immune responses against them as an adaptive
escape mechanism61. Among the discovered immune checkpoints, the
interaction between programmed death 1 receptor (PD-1) on T- cells and its
ligand programmed death-ligand 1/2 (PD-L1/2) on tumor cells or TILs as well as
the interplay between cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) on
T-cells and its ligand B7-1 (CD80) or B7-2 (CD86) on tumor cells or TILs. These
immune checkpoint pathways have been identified as critical immunosuppressive
mechanisms in cancer62,63 and, therefore, candidate targets. Nevertheless, the
education of immune cell types in the brain TME depends on tumor origin.
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1.5 Immune profiles in brain metastases derived from NSCLC
Characterization of the immune profiles is beneficial to provide a better
understanding basis for the precise treatment of brain metastasis. In mixed
cohorts (N = 252) of brain metastasis patients, the immune infiltrates distribution
was analyzed58. The authors described a highly heterogeneous distribution of the
immune infiltrates across brain metastases with three major patterns observed:
perivascular stromal infiltration (typically observed in NSCLC and other
carcinomas), peritumoral infiltration (lymphocytes surrounding brain metastases),
and homogenously diffuse infiltration (usually observed in melanoma). There was
no association between TILs, and overall survival (OS). Other studies have
demonstrated that TILs can infiltrate the stroma and peritumoral parenchyma of
brain metastases64. However, a high density of CD3+ or CD8+ cells was
positively correlated with OS56. Spatial diversity of immune infiltrates in matched
primary tumors and corresponding brain metastases was observed in patients
with NSCLC. Primary lung tumors had more positive TILs and PD-L1 expression
than brain tumor metastases 65. In another study containing a cohort of 20 paired
NSCLC primary tumor and brain metastases samples, T-cell receptor
sequencing showed a significant reduction of T-cell clones in brain metastases
compared with paired primary lung tumors despite the higher mutation burden in
brain metastases66. Furthermore, lower T-cell densities were documented in
brain metastases than primary lung tumors after sequencing T- cell receptor beta
(TCRβ) in a cohort of 78 samples from NSCLC primary tumors and paired brain
metastases. Nonetheless, the authors found a high frequency of shared T-cell
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clones between matched samples and proposed that the tumor
microenvironment of brain metastasis was more immunosuppressed than the
primary tumor. Accordingly, studies have investigated the T cell function and
distribution in advanced NSCLC lesions to identify a novel scheme to enhance
anti-tumor T cell immunity. However, insights into the role of the diversifiedmyeloid compartment at NSCLC sites are lacking.
1.6 Treatment of brain metastases from NSCLC
The majority of medical therapies for brain metastases include systemic
chemotherapies alongside whole-brain radiation therapy (WBRT) or stereotactic
radiosurgery (SRS), as well as molecular and immunotherapeutic approaches
aimed at shrinking tumors or inhibiting their growth15. The identification of driver
mutations in NSCLC has been translational in the management of brain
metastases. The most recent National Comprehensive Cancer Network NSCLC
guidelines (2019 version 4) recommend that tumor tissue needs to be tested for
EGFR, KRAS, HER2, ALK, ROS1, MET, BRAF, RET, and NTRK mutations67.
EGFR and ALK-targeted therapies are well established in oncogenic-driven
NSCLC and shown to have good CNS penetration, achieving intracranial
response rates between 40% and 80%68. Although a large number of patients
have oncogenic-driven NSCLC, a substantial proportion of patients do not have
such molecular alterations. The advancement of immune checkpoint inhibitors
(ICIs) has opened a new avenue of cancer treatment. Immunotherapy with PD-1
or PD-L1 inhibitors is a generally accepted treatment option for patients with
advanced lung cancer, whether as a single treatment or in combination with
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chemotherapy69,70. In the first-line KEYNOTE-189 trial69 and the second-line OAK
trial71, patients with immunotherapy-treated brain metastasis showed a more
prolonged overall survival (OS) than chemotherapy-treated. A recent phase 2
trial reported that pembrolizumab had effectiveness in brain metastasis from
NSCLC with PD-L1 expression at least 1%72. However, the efficacy of anti-PD1/PD-L1 treatments is improved in only a subset of brain metastasis patients.
There are still ongoing clinical trials assessing predictive biomarkers for the
effectiveness of ICIs in advanced NSCLCs. Nonetheless, recent discoveries
have shed light on the role of TME in tumor progression and therapy. ATP
encompasses a major component of TME73, communicates with immune cells,
and regulates their functions. A significant membrane channel that conducts
ATP is pannexins, which will be discussed in the following section.
1.7 Pannexins
Pannexins (PANXs) are a glycoprotein family of three members (PANX1, PANX2
& PANX3) that form channels for the passage of ions and other metabolites
involved in cell signalling74–76. They were discovered because of their limited
sequence homology to the invertebrate innexin gap junction proteins, and it was
initially considered that they could form gap junctions as vertebrate gap junction
proteins, connexins (CXs)74. Nonetheless, it soon became clear that the gap
junction function of PANXs is not their primary function, and there is a significant
sequence disparity between PANXs and CXs77. PANXs exhibit a similar topology
to CXs with four α-helical transmembrane (TM) domains, two extracellular loops
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(EL), and one intracellular loop (IL), with their amino (NT) and carboxyl (CT)
termini exposed to the cytoplasm74,78.
The NT region is the most preserved domain, but the highest sequence variance
is found in the CT domain79. PANX1 and PANX3 are more analogous to each
other compared to PANX280. Originally it was reported that six subunits of
PANXs oligomerize to form a channel, and these oligomers are named
‘pannexons’ that refer to single-membrane channels81. In contrast, the term
‘connexons’ for connexins refers to ‘hemichannels’(i.e., a structure constituting
half of a cell-cell channel)82. Recently, the structure of PANX1 has been
revealed, and the channel is now known to be formed by seven subunits83.
PANX1 and PANX3 genes are both located on chromosome 11, have (41%)
sequence similarity, and their proteins contain 426 (~48kDa) and 392 (~45kDa)
amino acids, respectively78. PANX2 gene is located on chromosome 22 and
encodes the largest protein among pannexin family members, containing 677
amino acids (~73kDa)80.
Pannexins are co-translationally embedded into the endoplasmic reticulum (ER)
84

and subsequently modified by N-linked-glycosylation that mediates cellular

localization of pannexins80,85. The glycosylation sites for PANX1 (N254) and
PANX3 (N71) were found to be in the second extracellular loop and the first
extracellular loop, respectively, whereas the site for PANX2 glycosylation is on
the first extracellular loop (N86)85. PANXs could be present as un-glycosylated
proteins (Gly0) or as high mannose species (Gly1) that mainly localize
intracellularly81,85. PANX1 and PANX3 are eventually transported to the Golgi
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apparatus and acquire more complex glycosylation (Gly2). Pannexins are
primarily localized at the cell membrane in this form85. Early on in this pathway,
pannexin monomers oligomerize and form non-selective channels that permit the
flux of molecules up to 1kDa in size, including ions and ATP75.

Despite the variance of sequences between pannexins and connexins,
pannexins show a matching structure to connexin hemichannels, and therefore,
they were initially proposed as a new gap junction family79,86. Nonetheless,
PANX1 and PANX3 can stay at the cell surface for more than 21 hours, but
connexins have a short half-life (1-5 hours)85,87,88. Additionally, pannexins
distribute throughout the cell membrane while connexins show particular
assembling at cell-to-cell contacts89. Gap junction formation by PANXs could be
prevented by glycosylation of the pannexin proteins80,81,90.

Pannexins have been identified in various cell types and tissues75. While PANX1
is widely expressed, PANX2 and PANX3 expression is more selective75. PANX3
has been reported in the skin, bone, and cartilage, including keratinocyte,
chondrocyte, and osteoblast. Panx3 has additionally been found in the lung, liver,
kidney, spleen, and thymus of 3-week-old three mice91,92. PANX2 was initially
thought to be expressed only in the central nervous system; however, it has
recently been identified in the skin, skeletal muscle, and the spleen93. The
expression of PANX1 will be discussed in the following section.
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1.8 Pannexin1
It was long thought that PANX1 monomer proteins oligomerize into hexameric
channels75,94,95 (Figure 2). However, recent research groups independently
revealed similar cryo-electron microscopy structures of the PANX1 channel that
appeared to be assembled in a homomeric heptamer83,96–98. This oligomerization
occurs intracellularly, mainly in the ER99, and then PANX1 can be trafficked to
the cell surface, where they have been characterized as conduits for ATP
release100,101. Under normal physiological conditions, Panx1 channels are
considered to be closed92. PANX1 is reportedly stimulated by several
physiological mechanisms95,102, including signaling pathways mediated by
membrane receptors103,104, elevated extracellular potassium 105or intracellular
calcium levels104, proteolytic cleavage by caspases100, hypoxemia106 and
membrane stretch, and voltage107. PANX1 channels can be closed by negative
feedback from extracellular ATP108 and by PANX1 channel blockers109. Studies
have proposed that the PANX1 channel may be regulated by the carboxyterminal end, which could reversibly close the pore110. However, cleavage of the
carboxy-terminal end by caspase 3 or 7 can open and activate the channel100.
PANX1 is the most characterized member of the three pannexins, presumably
because of its widespread expression in mammalian tissues75,111. Studies have
identified PANX1 expression in the heart, liver, testis, small intestine, ovary,
placenta, thymus, lung, pancreas, spleen, colon, and blood86. PANX1 expression
has also been found in different mouse brain structures, including the cerebral
cortex, hippocampus, cerebellum, and brain stem112. The presence of the PANX1
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protein in the skin, kidney, and ear cartilage has also been documented, and the
cardiac ventricular wall in 3-week-old C57BL/6 mice80.
The first physiological role attributed to PANX1 was a passage pathway for ATP,
allowing the outflow of ATP to function as a signal to cells via activation of
purinergic receptors101. Crucial evidence for ATP release mediated by PANX1
channels includes the localization of PANX1 expression corresponding to ATP
release at the apical membrane of polarized epithelial cells such as in the
airways or renal tubules113,114. Depletion of Panx1 channels additionally
diminishes ATP release108,110,115. PANX1 mutations and chemical modification of
the protein affect ATP release116,117. The ATP release-role of PANX1 has been
shown to affect Ca2+ waves, regulating the release of nitric oxide (NO) in the
smooth muscle of blood vessels and resulting in vasodilation when erythrocytes
respond to shear stress or hypoxia104. PANX1-associated ATP from leukemic
cells undergoing apoptosis can act as a “find me” signal and attract macrophages
and monocytes100. PANX1 channels can efflux inflammation-associated
cytokines upon an interaction between HIV1 and CD4+ cells 103,118. Increased
levels of extracellular K+ released in the brain activate PANX1 channels and
release ATP that causes neuronal hyperactivity in seizures of juvenile mice 119.
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Figure 2. Schematic representation of human PANX1 protein . PANX1 was
proposed as a tetra-spanning membrane protein with two extracellular loops and
amino and carboxyl termini exposed to the cytoplasmic side. N-linked
glycosylation site of PANX1 at N254 (yellow circle). The figure was generated
using BioRender.
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1.9 Pannexin1 in the respiratory system
ATP is a paracrine regulator of airway epithelial cell functions. Quantitative-PCR
showed PANX1 expression in normal human airway epithelial cells during redifferentiation at the air-liquid interface (ALI); immunohistochemistry confirmed
PANX1 expression at the apical pole of airway epithelia and Goblet cells113.
Genetic or pharmacological suppression of PANX1 expression in differentiated
airway epithelial cells hindered ATP release upon hypotonic stress by 60%113.
Additionally, PANX1 plays a role in the inflammatory component of asthma,
where inhibition of PANX1 in a murine model of asthma reduced the infiltration of
eosinophils in the peribronchial region120. Endothelial PANX1 has been shown to
play a vital role in regulating lung vascular inflammation and edema in response
to ischemia/reperfusion injury121.
1.10

Pannexin1 and immune cell recruitment

Recruitment of inflammatory cells to the injury site is driven by plenty of signals
that influence cell-cell interactions between vascular endothelial cells and
circulating leukocytes. In acute inflammation induced by tumor necrosis factoralpha (TNFα), PANX1 channels have been found to assist in the adhesion and
extravasation of leukocytes through the vascular wall 122.
PANX1 channels have been reported to play a role in the chemotaxis response
of neutrophils. Indeed, the activation of the chemoattractant receptors on the
surface of neutrophils controls PANX1-induced ATP release, which subsequently
stimulates P2Y2 receptors123. PANX1 channels play a role in generating

20 | P a g e

multinucleated macrophages124, the activation of T-cells125, and the migration of
leukocytes during inflammation123. In a cytokine-induced colitis model of human
colonic mucosal strips, the mucosal strips had less severe structural damage in
the PANX1 channel-blocker incubated group than the cytokines-only group126.
PANX1 channels have been linked to immune cell recruitment in leukemic cells,
releasing ATP as find-me signals for monocytes and macrophages, which may
regulate the crosstalk with other immune cells 100. However, PANX1 enhances
ATP-mediated T cell death in vitro127. Although PANX1 is implicated in the
process of inflammation and cell death, no study has looked at the role they play
in tumor-infiltrating lymphocytes in vivo. Nonetheless, a recently published study
has found that PANX2 mRNA expression in low-grade glioma had a significant
negative correlation with several immune cells, especially with macrophage,
dendritic cells, and CD4+ T cells128.
1.11

Pannexin1 in cancer and metastasis

Upregulation or amplification of PANX1 was documented in human biopsies
from most tumor types according to the analysis of cross-cancer alterations in the
89 cancer studies included on the cBioPortal.org for Cancer Genomics 129. Panx1
expression is listed in 17 out of 20 tumor types (high in colorectal, lung,
urothelial, and stomach cancers) (Human Protein Atlas130). Elevated expression
or an enhanced function of PANX1 have primarily been linked to the onset or
progression of cancer111. PANX1 expression has been reported at all stages of
human melanoma131; inhibition or deletion of PANX1 channels reduces the
growth, migration, and invasiveness of the melanoma cells131 as well as the
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number of liver metastasis from mouse melanomas in a chicken embryo
model132. A gain-of-function mutation in PANX1 channels enhances the
metastatic capability of breast cancer cells, particularly to the lung in a mouse
model107. At the same time, a pharmacological blockade or genetic deletion of
PANX1 everts epithelial-mesenchymal transition (EMT) in human breast cancercell lines133.
Moreover, overexpression of PANX1 increased invasion and migration of
testicular cancer cells, whereas genetic or pharmacological suppression of the
channel decreased tumorigenesis of the cells 134. In hepatocellular carcinoma
(HCC), PANX1 promoted the invasion and metastasis of HCC cells in vitro and in
vivo and was an independent prognostic factor for HCC patients 135. Additional
illustrations include the human glioma cell line U87-MG that significantly declined
proliferation after PANX1 siRNA treatment136. Similarly, higher expression of
PANX1 is found in human leukemic lymphocytes compared to normal T cells137
and in aggressive multiple myeloma cell lines138. Therefore, PANX1 plays a role
in the progression of multiple tumors.
Although most reports in the literature demonstrated an increased level of
PANX1 in cancer cells, there are also important exceptions. A study documented
that although PANX1 mRNA was expressed in primary astrocytes, the C6 rat
glioma cell line did not express it, and overexpression of PANX1 in C6 glioma
cells resulted in tumor suppresion139. The same authors of the study reported
that four human glioma cell lines (U87, U251, SF188, and SF539) were positive
for PANX1 at the transcript level, indicating some differences in PANX1
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expression among species in gliomas139. Furthermore, PANX1 levels are
significantly reduced in gallbladder adenocarcinoma compared to normal
gallbladder epithelium and correlated to the proliferative activity of the cells 140.
Recently, a study has shown that PANX1 expression is down-regulated in cell
lines of alveolar rhabdomyosarcoma (aRMS) and embryonal rhabdomyosarcoma
(eRMS)141. These cases constitute the few notable exceptions to the general
idea that PANX1 tends to be upregulated in tumors compared to normal tissues.
1.12

Rationale

The variance in brain metastasis progression and tumor-infiltrating immune
profile among metastatic lung carcinoma patients requires robust- predictive
biomarkers. The role of PANX1 in the progression and immune landscape of lung
cancer-derived brain metastases has not been explored yet.
The criterion of clinical cancer treatment has deviated towards using immune
checkpoint inhibitor (ICI) treatments. The ICIs have shown promising clinical
effects in NSCLC142. However, only a subset of patients shows responsiveness
to the treatment. The predictive and prognostic biomarkers for ICIs efficacy have
considered the expression levels of immune checkpoint genes PD-1, PD-L1,
CTLA4, and mutational burden in cancer samples 143,144. The heterogeneity of the
tumor microenvironment around tumor cells was not investigated144. TME
significantly contributes to cancer development and malignancy145, and the tumor
immune microenvironment (TIME) plays a significant role in tumor immune
surveillance and immunological evasion146,147. In the TME, ATP significantly
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impacts tumor progression and metastasis148; among the channels that conduct
ATP across the plasma membrane are channels formed by PANX1100. Therefore,
investigating the role of PANX1 in the crosstalk between lung carcinoma cells
and immune cells is vital. There is no published work on the relationship between
PANX1 and immune cells within a tumor, nor the correlation of PANX1
expression in the primary lung- and metastatic brain tumors.
1.13

Hypothesis

PANX1 expression is upregulated in brain metastases compared to
corresponding primary lung carcinomas and is linked with a lower density of
tumor-infiltrating immune cells.

1.14

Aims

1) Assess protein levels of PANX1 in brain metastases and patient-matched
primary lung carcinomas.
2) Investigate the density of T-cells and macrophages in brain metastases
and corresponding primary lung carcinomas in human specimens.
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Section 2: Methods
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2.1 Patient Cohort
This study was approved by the Western University Health Science Research
Ethic Board (HSREB 111911). Forty-two patient-matched formalin-fixed- paraffinembedded tissue (FFPE) samples of lung carcinomas in the lung and
subsequent metastases in the brain between 2005 and 2015 were provided by
the London Health Sciences Centre. The cohort contains 42 FFPE NSCLCs,
where the majority of the cases are adenocarcinoma phenotype. The clinicalhistological characteristics of the patients are described in table 1.
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2.2 Tissue Microarray (TMA)
After performing 4μm sections, slides were reviewed by local pathologists using
hematoxylin and eosin-stained preparations149 to select representative tumor
areas. Each case was represented by three cores (0.6 mm2 each) obtained from
a primary lung carcinoma block followed by three cores constructed from
matched-brain metastasis block and eventually arrayed in two recipients TMAmaster-blocks as illustrated in figure 3. Finally, FFPE specimens of the nontumor brain and placenta were used as controls. The histological diagram below
describes the structure of our TMA150,151.
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Figure 3. Schematic Structure of TMAs. The first row was obtained from FFPE
human non-tumor brain tissues (A1 and A2) and placenta (A3 and A4) and used
as a control and instructor. Each case was represented by three cores
constructed from primary lung tumor block (cores B1, B2, and B.3) followed by
three cores obtained from matched brain metastasis block (cores B4, B5, and
B6). Scale bar= 200 μm.
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2.3 Immunohistochemistry (IHC)
IHC was performed on four μm-thick sections from TMA master blocks. Slides
were then immediately transferred to fresh 100% xylene and processed through
an ethanol hydration gradient (100, 90, 70, 50% ethanol solutions for 5 min each)
before immersion in distilled water. After deparaffinization, immunochemistry was
performed as previously described152. Briefly, sections were washed thrice in
phosphate buffer saline (PBS), boiled in 10mM sodium citrate solution for antigen
retrieval, blocked in PBS with 2.5% horse serum for 1 hour, washed thrice with
PBS, and eventually incubated overnight at 4 °C with primary antibodies. AntiPANX1 antibody (1:200; rabbit polyclonal)80, anti-CD3 (1:500, mouse
monoclonal, DAKO), anti-CD4 (4B12, mouse monoclonal, DAKO), anti-CD8
(1:250; Mouse monoclonal,DAKO), anti-CD68 (1 : 200; mouse monoclonal,
Dako) and anti-PD-L1 (1:200; mouse monoclonal, DAKO), TTF1 (1:50;
monoclonal, DAKO), CK7 (1:50; monoclonal, DAKO), CK20 (1:50; monoclonal,
DAKO), and TMEM119 (1:100; Abcam).
2.4 QuPath Software
TMAs were digitized and quantified using an open software QuPath153
(https://qupath.github.io/), a digital pathology software to quantify stained images.
It can process whole slide images up to 40 G.B. and evaluate IHC staining. It
averages a variation of staining intensity with the ability to detect total tissue
areas or areas of interest. The H-score takes into account both staining intensity
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and percentage of cells stained, giving a range of 0–300 using the following
formula: 1× (% cells +) + 2 × (% cells ++) + 3 × (% cells +++). Overall scores
were averaged from triplicate cores for each tissue type in each patient, and a
minimum of 200 tumor cells was evaluated. Initially, H &E slides from TMAs were
reviewed then the representative areas of the tumor were annotated manually
based on tumor histomorphology and confirmed by immunohistochemistry using
Pan-CK. Necrotic and hemorrhagic regions were excluded. H&E annotations
were copied on IHC stained TMAs to quantify protein levels (Figure 4). Cores
unsuitable for analysis, either with no tumor tissue or significant artifacts, were
excluded. H-Scores were also averaged from triplicate cores. The TMA cores
below illustrate how to select tumor cells and exclude other153–155. CD3, CD4,
CD8, CD68, and PD-L1 analysis were classified as either positive or negative for
the marker and quantified as a percentage of positive cell numbers relative to
lung carcinoma cell numbers58.
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Figure 4. Illustration of QuPath software annotation. Manually, tumor cells in
IHC-stained cores were annotated, and other cell types were excluded after
histological analysis based on H&E-stained cores—Scale bar= 100 μm.

32 | P a g e

2.5 Immunofluorescence
TMA blocks were sectioned into four μm-thick, deparaffinized, and immunolabeled with PANX1-CT primary antibody (stock 1 μg/μl) in a 1:100 dilution as
described previously156. Briefly, slides were immersed with descending alcohol
(100%, 95%, 70%, 50%) for rehydration, washed with PBS, and warmed in
vector lab- antigen unmasking solution (H-3300), blocked with 3% B.S.A. and
0.1% Triton X-100 in PBS for an hour and then incubated with primary antibodies
overnight at 4°C. Sections were washed three times with PBS and incubated with
appropriate species-specific secondary antibodies conjugated with Alexa 488 or
647 for 60 minutes at room temperature and then counterstained with Hoechst to
visualize nuclei. Sections were cover-slipped using a fluorogel mounting medium.
Immunofluorescence images were obtained using a Zeiss LSM 800 Confocal
Microscope with a Plan-Apochromat 63x/1.40 Oil DIC objective (Carl Zeiss).
Peptide competition was conducted as described previously156.
2.6 Statistical Analysis
Statistical analyses were performed using GraphPad Prism (version 9.1.2).
Comparison analysis is represented by a plot of symbols & lines with a graph
family of a column as individual values. Correlation graphs were performed by
computing Pearson correlation coefficients and displayed as a graph family XY.
The correlation between metastatic time interval and a level of PANX1 in NSCLC
was performed by a Kaplan-Meier Curve. The thresholds for PANX1 levels were
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determined by tertiles and quartiles. p-values were calculated by parametric,
paired-two-tailed Student’s t-test for all graphs.
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Section 3: Results
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3.1 Metastatic cells in the brain retained the immuno-histochemical profile
and strongly correlated with their primary tumors.
In the NSCLC-brain metastasis cohort, all metastatic cells in the brain specimens
had the same immune profile as their matched-NSCLC specimens. They were
positive for thyroid transcription factor 1 (TTF-1) and cytokeratin 7 (CK7) but
negative for cytokeratin 20 (CK20) (Figure 5). The triple markers (TTF-1+, CK7+,
CK20-) outline is widely used to diagnose primary NSCLC149. Figure 5 shows a
positively strong correlation of TTF1 and CK7 between primary lung cases and
their matched brain metastases.
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Figure 5. Brain metastases preserve the immunohistochemical profile of
NSCLC. A representative image of IHC with antibodies raised against TTF1,
CK7, and CK20 in primary NSCLC and matched-brain metastasis cores.
Metastatic cells in the brain have the same immune-histology profile as in
NSCLC tissue, indicating that the metastatic cells in the brain originated from
lung carcinoma. Images are shown with a 200-μm resolution. B Positive
correlation of TTF /CK7 between NSCLC and brain metastases. Scatter Plot
shows a positive correlation, where Pearson r>0.8+ and p<0.0001 for TTF-1,
p=0.0024 for CK 7, indicating a strong positive correlation.
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3.2 Protein levels of PANX1 were significantly higher in brain metastases
compared to corresponding primary lung tumors.
Protein levels of PANX1 were assessed in the NSCLC-brain metastasis cohort
(N=42 cases). Each patient was represented by three cores from an NSCLC
sample and three cores from its matched sample of brain metastasis and
constructed by TMA. TMA blocks were sectioned and stained independently with
H&E and anti-PANX1 antibody131. H&E and PANX1 staining were visualized and
then analyzed by QuPath; carcinoma cells of both samples were selected
manually based on H&E morphology and confirmed by a pathologist. Next, the
staining intensity of PANX1 in three cores of each representative sample was
averaged, considering that (+) is weak staining, (++) is a medium staining, and
(+++) is intense staining (Figure 6.A). The staining intensity was assessed using
an H-score variable on QuPath software described above. Next, PANX1 levels
(H-scores) in NSCLC and brain metastases were statistically compared. A
protein level of PANX1 was significantly higher in brain metastases in
comparison to matched-NSCLC (Figure 6.A). The correlation between PANX1
levels of primary NSCLC and PANX1 levels of brain metastasis was then
assessed. Interestingly, PANX1 levels of NSCLC were strongly and positively
correlated with PANX1 levels of brain metastases, where Pearson coefficient r
was >0.6 (Figure 6.B). This indicates that a level of PANX1 in an NSCLC may
predict the level of PANX1 in a matched-brain metastasis case; an increase of a
PANX1 level in lung carcinoma cells would lead to an increased level of PANX1
in metastasizing-lung carcinoma cells in the brain. Notably, the exact correlation
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was found when assessing PANX1 levels of primary NSCLC and PANX1 levels
of matched-metastatic lymph nodes in PANX1 (Supplementary section, Figure
S1). Further, the expression of PANX1 was investigated in two smaller cohorts of
brain metastasis patients with breast cancer and melanoma, and their analyses
can be found in the supplementary figures section, figure S3.

39 | P a g e

Figure 6. PANX1 expression is higher in brain metastases compared to
matched- NSCLC. A representative image of I.H.C with an anti-PANX1 antibody
on TMAs. The upper panel represents NSCLC cores, and the lower panel
represents matched brain metastasis cores; representative areas of tumor were
selected by analyzing the morphology of cores based on H&E- stained slides
then traced carcinoma cells using QuPath software. Cores were categorized into
‘intensity’ groups (+, weak staining) and (++, medium staining). Images scanned
at 20X objective magnification. Paired T-test of PANX1 levels between NSCLC
and matched-brain metastases shows that PANX1 of brain metastases is
significantly higher than PANX in NSCLC (****P=<0.0001). The total number of
cases was 42, but outliers were excluded (n=35). Scale bar=100 μm. B Scatter
Plot shows a strong positive correlation between PANX1 levels in lung tumors
and brain metastases (Pearson coefficient =0.63), and this correlation was
statistically significant (***P>0.0001).
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3.3 Brain metastases exhibited higher levels of β-catenin compared to
NSCLC
Levels of β-catenin, a key member of the Wnt signaling pathway, were evaluated
in brain metastases and NSCLC. β-catenin has been linked to enhancing
metastasis in different tumors157–159 and playing a role in lung tumorigenesis14.
More importantly and recently, Sayedyahossein et al. discovered a direct
interaction between β-catenin and PANX1 in melanoma cells160. Additionally, it
has been demonstrated that deletion of PANX1 pharmacologically or genetically
decreased the levels of β-catenin and indicated a reverse of EMT in human
breast cell lines133. Therefore, β-catenin levels were evaluated in NSCLC and
brain metastases and tested a correlation between them. Levels of β-catenin
were quantified in both samples using QuPath and then performed a paired ttest. The β-catenin level was significantly higher in brain metastases than in
NSCLC (Figure 7.A). There was no significant correlation of β-catenin between
NSCLC and brain metastases (Figure 7.B). Next, a correlation between β-catenin
levels and PANX1 levels in NSCLC was tested. There was no statistically
significant correlation (Figure 7.C).
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Figure 7. β-catenin expression is higher in brain metastases compared to
NSCLC. A representative image of IHC with an antibody raised against b βcatenin shows that the staining is more intense in BM. Paired T-test between βcatenin of NSCLC (blue dots) and beta-catenin of BM (red dots) shows a
significant difference between the groups (*P=0.011). Scale bar= 100 μm. B
Scatter Plot of β-catenin levels in brain metastases and primary NSCLC shows
no correlation, where Pearson variable (r=0.16). C Scatter Plot between PANX1
and β-catenin levels in lung tumors shows no statistically significant correlation
(Pearson r=-0.1355).
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3.4 There was no statistical correlation between PANX1 levels of NSCLC
and metastatic time interval.
The time interval of the NSCLC cases to metastasize to the brain ranges from (0120) months. The Histogram (Figure 8.A) shows the distribution of the cases
based on a time interval to metastasize to the brain, where most cases have a
time interval of >= 20 months. A correlation between PANX1 levels of NSCLC
and the time interval to metastasize to the brain was investigated. NSCLC cases
were split into two groups, high PANX1 and low PANX1, determining the
thresholds by a median, tertiles, and quartiles 151, and applied the two groups on
a survival curve (Figure 8.B); other thresholds are shown in figure S.2. There was
no statistically significant correlation.
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Figure 8. There is no significant correlation between the PANX1 level of
NSCLC and metastatic time intervals. A Distribution of NSCLC cases (N=42)
is displayed based on PANX1 (H-score) levels and a time needed to metastasize
to the brain. B Survival curve between two groups of PANX1 level (high vs. low)
in primary NSCLC and the time intervals to metastasize to the brain. The X-axis
indicates the time intervals of primary NSCLC to metastasize, whereas the y-axis
shows the percentage of NSCLC cases without brain metastases. Quartiles
determined the thresholds of the PANX1 level (H-score).
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3.5 PANX1 distributed predominately in the cytoplasm of carcinoma cells in
primary NSCLC and corresponding brain metastasis.
Next, the cellular localization of PANX1 was investigated to assess any
differences between primary NSCLC and matched brain metastases. Therefore,
immunofluorescent staining was performed on the TMA with an antibody raised
against PANX1. PANX1 in the brain metastases and NSCLC specimens was
located predominantly in intracellular compartments of carcinoma cells (Figure
9).
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Figure 9. PANX1 is distributed in the cytoplasm in NSCLC and brain
metastases. Representative images of IF (N=21) using an anti-PANX1 antibody
in NSCLC (upper panel) and brain metastasis samples (lower panel). Hoechst
staining is displayed in blue color, whereas PANX1 in green. The column (merge)
has PANX1 staining and Hoechst staining. The columns (only secondary
antibody and peptide+) show validation of the specificity of the anti-PANX1
antibody. PANX1 was mainly distributed intracellularly in lung carcinoma cells in
the lung and brain. Scale bar=20μm.
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3.6 High levels of PANX1 were associated with less infiltration of bloodderived macrophages in brain metastases.
Next, the correlation between the level of PANX1 and the immune infiltration was
assessed. Therefore, immunohistochemical staining was conducted
independently on TMA using anti (CD3, CD4, CD8, CD68, and PD-L1)
antibodies. First, the density of these immune markers was compared between
NSCLC samples and their matched brain metastases using QuPath software,
performing a percentage of positive cells for the immune marker relative to all
lung carcinoma cells within each core and averaging the density in 3 cores of
each case sample58. CD3+, CD8+, and CD68+ cells were more infiltrated in
NSCLC (Figure 10.A) compared to their paired brain metastases. Next, the
percentages of CD3+, CD8+, CD4+, and CD68+ cells infiltration to the total
tumor were applied on a paired T-test and found the density of immune markers,
CD3, CD8, and CD68, were significantly higher in NSCLC compared to their
densities in brain metastases. In contrast, there was no statistical significance in
CD4+ cell infiltration between NSCLC and brain metastases (Figure 10.B).
Because CD68 expression profiling does not precisely distinguish between
peripherally derived macrophages and brain resident microglia, the expression of
TMEM119 (a microglia marker)161 was assessed using IHC on TMAs (Figure
S.4). Cores of normal adjacent tissues to brain metastases (NAT) from the TMAs
and external-brain tissues of leukodystrophy disease (LD) were used as positive
controls for TMEM119. The analysis showed that most CD68+ immune cells in
the brain metastases were negative for TMEM119 (Figure S.5); therefore, CD68+
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cells represented blood-derived macrophages. Subsequently, an evaluation of
the correlation between CD8+ or CD68+ cells infiltration in NSCLC and
metastatic time intervals was performed. Lung tumor cases were split into two
groups, high density of CD8+ or C68+ cells and low density of CD8+ or CD68+
cells, taking a median percentage as a threshold and applying the inputs on the
survival curve. Neither the density of CD8+ cells nor the density of C68+ cells in
NSCLC correlated with a time interval to metastasize to the brain (Figure S.6).
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Figure 10. The densities of CD3+, CD8+, and CD68+ cells are higher in
NSCLC compared to BM. A Representative image of H&E and IHC with
antibodies raised against CD3, CD4, CD8, and CD68 on TMA slides. The density
of these immune markers was assessed through QuPath software by performing
a percentage of CD3, CD8, CD4, and CD68+ cells infiltration relative to all
carcinoma cells within NSCLC and BM cores. Scale bar= 100 μm. B Paired Ttest was performed to compare the infiltration of these immune cells between
NSCLC and BM. The test shows significantly higher infiltration of CD3, CD8, and
CD68 in NSCLC compared to matched brain metastases, N=35, where outliers
were excluded.
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Additionally, due to the significance of PD-L1 expression level for the efficacy of
ICIs in lung carcinoma143,162–165, PD-L1 levels of carcinoma cells were assessed
by performing a percentage of PD-L1+ cells relative to all carcinoma cells within
each core143. PD-L1 expression was higher in NSCLC compared to brain
metastases (Figure 11.A). By performing a correlation plot between PANX1
levels and PD-L1 levels of carcinoma cells, there was no statistically significant
correlation neither in NSCLC nor brain metastases (Figure 11.B).
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Figure 11. There is no correlation between PD-L1 and PANX1 in NSCLC or
BM. A Representative image of NSCLC and BM cores was stained
independently with H&E and PD-L1. PD-L1 expression was assessed using
QuPath by the percentage of PD-L1+ carcinoma cells relative to total tumor cells
within a core and then compared between NSCLC and BM using paired t-test.
PD-L1 significantly expressed higher in NSCLC (*p=0.016). Scale bar= 100 μm.
B Correlation plot was performed between PD-L1 of carcinoma cells and PANX1
of carcinoma cells in NSCLC and BM. There was no statistically significant
correlation, where Pearson r=0.34 and 0.2 respectively.
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Next, a correlation was tested between PANX1 levels of carcinoma cells and
CD3+, CD8+, or CD68+ cells infiltration. There was no correlation between
PANX1 levels and the density of CD3+, CD8+ or CD68+ cells in NSCLC (Figure
12.A, B, &C). There was no correlation between PANX1 levels of carcinoma cells
and the density of CD3+ or CD8+ cells in brain metastases (Figure 12.D &E).
Interestingly, there was a negative correlation between PANX1 levels of
carcinoma cells and the density of CD68+ cells in brain metastases. Pearson
coefficient was (-0.405) (Figure 12.F), pinpointing that a higher level of PANX1 in
metastatic lung carcinoma cells is associated with less infiltration of
macrophages in the brain.
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Figure 12. PANX1 of lung carcinoma cells is associated with less infiltration
of blood-derived macrophages in BM. A, B &C Scatter Plot shows no
statistical correlation between PANX1 levels of carcinoma cells and the
percentage of CD3+, CD8+, or CD68+ cell infiltrations in NSCLC. D&E Scatter
plots between PANX1 levels of carcinoma cells and the percentage of CD3+,
CD8+, CD68+ cell infiltrations in BM. There was no significant correlation
between PANX1 levels and the infiltration of CD3+ or CD8+ cells. F Scatter Plot
between CD68+ cells infiltration and PANX1 levels of lung carcinoma cells in BM
shows a significantly negative correlation, where (Pearson r= -0.40) and
(*P=0.0142), indicating that a high- PANX1 level of lung carcinoma cells is
associated with a lower infiltration of blood-derived macrophages in BM.
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Graphical Summary
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Section 4: Discussion
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PANX1 has not been characterized in NSCLCs nor brain metastasis of patientderived specimens at a protein level. Brain metastases are primarily originated
from NSCLC and represent the leading cause of cancer-associated death.
Although clinical trials showed a promising effect of immune checkpoint inhibitors
in asymptomatic brain metastases due to NSCLC, there remains a robust
demand for new biomarkers that effectively anticipate response to ICIs166.
Furthermore, a PANX1 role has not been identified in the immune landscape in
tumors. Here, we investigated the expression of PANX1 and immune profiling in
primary NSCLCs and matched brain metastases. For the first time, we
demonstrated that (i) brain metastases derived from NSCLCs exhibit higher
expression of PANX1, (ii) less density of CD3+, CD8+, and CD68+ immune cell
infiltrations in comparison to primary NSCLC, and (iii) higher PANX1 in brain
metastases was associated with less infiltration of blood-derived macrophages.
Our results suggest that PANX1 plays a role in lung carcinoma progression and
immune profiling of metastatic lung carcinoma.
The role of PANX1 in tumorigenesis and metastasis progression has been
documented in different malignancies. PANX1 has been, for instance, found
across three stages of patient-derived melanoma tumors- in primary sites of
melanoma, metastatic lymph nodes, and distal metastasis sites 131. PANX1
expression was higher in melanoma tumors than normal skin without a significant
difference among the tumor stages. In melanoma cell lines, PANX1-depleted
cells had less growth and migration compared to PANX1-abundant cells131. In a
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chicken embryo model, implanted BL6 mouse melanoma tumors derived from
PANX1 knockdown cells were significantly smaller, contained less blood, and
metastasized with less number of mouse cells to the liver compared to those
derived from control cells132. The human melanoma cells with PANX1 blocked by
pharmacological inhibitors showed reduced invasiveness in the primary tumors,
although distant metastasis could not be evaluated131. Nonetheless, in
hepatocellular carcinoma (HCC), PANX1 expression levels were positively
correlated with the TNM classification of malignant tumors in human-derived
specimens135. Patients with high PANX1 expression in tumors displayed a more
advanced disease state than patients with low expression of PANX in tumors.
Additionally, PANX1 overexpression significantly induced metastasis in HCC cell
lines and inducible mice by promoting EMT through AKT signaling135. In breast
cancer, a gain-of-function mutation of PANX1 channels enhances the metastasis
capability of tumor cells to disseminate to the lung, bone, and liver in a mouse
model107. Pharmacological inhibition of PANX1 in breast cancer cells or genetic
deletion of PANX1 retrogressed the EMT phenotype133.
The TME is considered a fundamental regulator of cancer progression, and
Adenosine triphosphate (ATP) is one of the critical biological compounds of
TME167. PANX1 may enhance the progression of lung carcinoma through ATP
release in association with other purinergic receptors168. However, PANX1
distributed intracellularly in NSCLCs and brain metastases in our cohort,
suggesting a different role than PANX1 at the cell membrane. PANX1 at a cell
membrane is involved in the conductance of ATP and molecules that are less
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than (1) kDa under pathophysiological conditions. Intracellular PANX1, however,
could be involved in WNT/ β-catenin signaling pathway160. β-catenin is essential
for the progression of mutated EGFR lung carcinoma, accounting for
approximately 20% of mutations in NSCLC14. β-catenin, the main component of
WNT/TCF signaling, additionally mediates lung adenocarcinoma metastasis to
the brain169. We found that β-catenin expression is higher in brain metastases in
comparison to NSCLC, demonstrating the role of β-catenin in the progression of
advanced lung carcinoma in association with PANX1. Previously, it was shown
that PANX1 and β-catenin interact to modulate the growth and metabolism of
melanoma cell lines160. Nonetheless, PANX1/ β-catenin interaction may still exist
in these carcinoma cells since they co-express both proteins that have been
shown to interact directly. Furthermore, intracellular PANX1 could locate in the
ER, evoking calcium release from internal stores in prostate cancer cells 170, and
we know that Ca2+ plays a significant role in metastasis171. Therefore, it is
possible that the signaling that occurs via intracellular PANX1 has more to do
with calcium signaling than with other functions at the cell surface. Further,
studies have linked PANX1 and metastasis through the EMT pathway, where
inhibiting PANX1 channels pharmacologically or genetically led to a decrease of
vimentin, β-catenin, snail, and slug133,135. PANX1 has also been linked to
metastasis by activating the ERK1/2 pathway in I-10 testicular cell lines134.
Therefore, intracellular PANX1 could be essential for the metastasis cascade
through activating signaling pathways, such as Ca+2 signaling in the ER170, EMT
pathway135, AKT/PI3K pathway134, or the Wnt /beta-catenin pathway160.
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The level of PANX1 in primary NSCLCs did not correlate with the metastatic time
interval. However, there was a tendency of lung carcinoma cases with high levels
of PANX1 to metastasize to the brain earlier, particularly with less aggressive
cases. Here, we found that high PANX1 in 11 cases with >=20-month of
metastatic duration needed less time to metastasize to the brain. Nonetheless,
the sample number needs to be more significant to conclude. Aggressive
mutations could drive the metastasis progression in the cases (n=31) with 20
months > time intervals.
Evaluating the immune profile in brain metastases is essential in light of immune
checkpoint blockade treatments, which have shown efficacy in clinical trials using
anti-PD-1/PDL-1 antibodies in asymptomatic brain metastasis patients with
primary lung carcinoma166. Our study found that the infiltration levels of
CD3/CD8/CD68+ cells in primary lung carcinoma were higher than in brain
metastases. Primary lung tumors have more immune infiltration than their
metastases in the brain since they have been established longer and have
developed more immunological mechanisms. However, neither the density of
CD8+ immune cells nor the density of CD68+ immune cells in primary NSCLC
was correlated with the metastatic time interval.
Our study found that primary lung carcinoma cells have higher expression of PDL1 than metastatic lung carcinoma cells in the brain by IHC assessment. PANX1
was not correlated with PD-L1 expression in NSCLC nor in brain metastasis. We
additionally revealed that PANX1 expression of metastatic lung carcinoma in the
brain was associated with less infiltration of macrophages. PANX1 channel
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activity has been linked to the recruitment of immune cells through ATP signaling
in non-tumor conditions122,172. However, the role of PANX1 in immune status in a
cancer context has not yet been explored. Our observation could be attributed to
several factors, such as that PANX1 channels are more intercellular than at a cell
membrane in lung carcinoma cells. Therefore, the theory of PANX1 releasing
ATP as a signal “find me” for immune cells may have less contribution in the
malignancy context.
Additionally, macrophages are physiologically subtyped into M1 (proinflammatory) and M2 (anti-inflammatory); therefore, it could be related to the
pathophysiology of a macrophage phenotype. On the other hand, macrophages
also express PANX1173, which might play an anti-inflammatory role in metastatic
lung carcinoma cells in the brain. Further studies on a different model are needed
to assess the interplay between PANX1 and macrophages in brain metastases
derived from NSCLC.
In immunotherapy applications, PD-L1 of tumor cells was utilized as predictive
markers for assessing the efficacy of ICIs143. Additionally, PD-L1 of TME has
recently been considered an additional component to evaluate the PD-L1
status143. In NSCLC, the predominant immune cell type that expresses PD-L1 is
CD68 macrophages162. Interestingly, recent studies documented that the level of
PD-L1 in macrophages is correlated with longer OS in melanoma151 and NSCLC
patients162 treated with anti-PD-1/PD-L1 therapies. Hence, pharmacological
blockade of PANX1 channels could play a reverse effect and attract more
macrophages in brain metastases and subsequently have greater expression of
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PD-L1 in TME, which may enhance the effectiveness of ICIs in advanced
NSCLC. Further studies are required to evaluate this notion.
Limitation of the study and future directions
This study investigated the significance of PANX1 in the progression of brain
metastases derived from NSCLC, but it still has some limitations. Although high
expression of PANX1 in primary lung carcinoma can predict a higher level of
PANX1 in brain metastases, it lacks clinical applications, such as predicting the
metastatic time interval. Additionally, despite the confirmation that PANX1 is
upregulated in brain metastases and correlated with less infiltration of
macrophages, we did not provide the detailed mechanism nor identify the subset
of macrophages in brain metastases. Further, immune markers often have a high
level of heterogeneity; therefore, accurate representation of the tumor and the
TME is essential151. For our study, we used three nonadjacent TMA cores for
each patient to minimize sampling errors, but this still represents a very small
percentage of a standard tissue section.
Immunohistochemistry in pathological anatomy and digital pathology supports
subjective perception and directly corresponds to the experience of the hands
and the expertise in interpreting the results174,175. Therefore, immunostaining
methods can be variable and may present significant bias. Hence, its outcomes
must be interpreted with caution.
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However, the study unravels the role of PANX1 in the progression of metastatic
NSCLC to the brain and highlights the association of NSCLC PANX1 with the
immune landscape in brain metastasis, paving a new avenue for a treatment
approach that may enhance the efficacy of ICIs. Future directions of our study
would investigate the mechanism of the cross-talk between PANX1 of lung
carcinoma cells and blood-derived macrophages in brain metastasis in a mouse
model, where the levels of PANX1 in different cell types could be modified, and
the use of PANX1 blockers could be evaluated.
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Section 5: Supplementary Figures
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Figure S.1. Expression of PANX1 had a positive correlation between
primary NSCLC and matched metastatic lymph nodes. Here, we have 12
patients with NSCLC that subsequently metastasized to lymph nodes and the
brain. A T-test was applied on levels of PANX1 in lung tumors and their
metastases in lymph nodes or B on PANX1 levels in metastatic lung tumor cells
in the lymph nodes and brain and shows no statistical significance. N=12
patients, H-score refers to levels of PANX1. C Correlation plot of PANX1 levels
between NSCLC and metastatic lymph nodes or D between metastatic lymph
nodes and brain metastases. PANX1 levels of NSCLC correlated positively and
significantly with PANX1 levels of lymph nodes (Pearson r=0.76, **p=0.04),
whereas this correlation was not significant between PANX1 levels of lymph
nodes and PANX1 levels of brain metastases.
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Figure S.2. Additional thresholds of PANX1 in primary NSCLC determined
by quartile and tertile. Thresholds were applied on a survival curve, where the
X-axis indicates metastatic interval (months) to the brain and the Y-axis indicates
percentages of primary NSCLC without brain metastases. There was no
significant correlation between the PANX1 level of primary NSCLC and
metastatic interval to the brain.
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Figure S.3. Expression of PANX1 in breast tumors or melanoma and
matched-brain metastases. For the breast tumor-brain metastasis cohort, we
had 11 patients with breast tumors that metastasized to the brain. A IHC using
anti-PANX1 antibody on TMA cores of breast tumor and brain metastases. We
analyzed the staining intensity of tumor cells in breast tissue cores and brain
metastasis cores by QuPath after tracing them based on H&E staining; the
staining was more intense in breast tumors (Moderate, ++) compared to brain
metastases (weak, +). B Statistical quantification of PANX1 levels in breast
tumors and brain metastases using t-test; PANX1 levels were significantly higher
in breast tumors than matched-brain metastases, where p=0.0187 and H-Score
refer to PANX1 levels. C Correlation plot of PANX1 between breast tumors and
brain metastases. It was a negative correlation with no statistical significance;
however, the correlation neared a statistical significance, and increasing the n
value might achieve that. Thus, the more PANX1 level is in breast tumors, the
less PANX1 level would be in brain metastases. For the melanoma-brain
metastasis cohort, seven patients had melanomas and metastasized to the brain.
D IHC using anti-PANX1 antibody on TMA cores of melanoma-brain metastases;
the staining intensity was strong (+++) in melanomas and brain metastases. E Ttest was applied on levels of PANX1 in melanoma and their metastases in the
brain and showed no statistical significance, where N=7 patients, H-score refers
to levels of PANX1. F correlation plot of PANX1 levels between melanomas and
brain metastases shows no statistical correlation, where Pearson r=0.3378.
Images are displayed with a 100-μm resolution.
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Figure S.4. Brain metastasis cores are negative for the microglia marker,
TMEM119. Representative images of brain metastasis core stained with H&E
and IHC using antibodies raised against TMEM119. Positive controls used are
normal brain tissues next to brain metastases (NAT) that have an abundance of
microglia and, therefore, were stained intensely with TMEM119 antibody. Another
positive control used for the TMEM119 antibody is an autopsy from the
leukodystrophy case (LD), which pathologically has a reduction in the microglia
population, stained weakly with the TMEM119 antibody. Scale bar= 100 μm.
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Figure S.5. Infiltrated CD68+ cells in brain metastasis regions are
macrophages derived from blood. Distribution of BM cases stained with
TMEM119 antibody. The majority of BM cases were native for TMEM119 and
positive for CD68, indicating that CD68+ are macrophages derived from blood,
not microglia.
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Figure S.6. There is no correlation between the infiltration level of CD8+ or
CD68+ cells and the metastatic time interval. Survival curve applied on the
group of a high density of CD8+/CD68+ cells vs. the group of a low density of
CD8+/CD68+ cells in NSCLC. The X-axis indicates time intervals to metastasize
to the brain, whereas Y-axis indicates the percentage of NSCLC cases without
brain metastases. ‘ns’ denotes no statistical significance between the two groups.
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Appendix

Date: 6 May 2021
To: Dr. Qi Zhang
Project ID: 111911
Study Title: Discovering Predictive Biomarkers of Brain metastatic tumors and
rare gliomas
Application Type: Continuing Ethics Review (CER) Form
Review Type: Delegated
REB Meeting Date: 18/May/2021
Date Approval Issued: 06/May/2021
REB Approval Expiry Date: 22/May/2022
________________________________________________________________
Dear Dr. Qi Zhang,
The Western University Research Ethics Board has reviewed the application.
This study, including all currently approved documents, has been re-approved
until the
expiry date noted above.
REB members involved in the research project do not participate in the review,
discussion or decision.
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Western University REB operates in compliance with, and is constituted in
accordance with, the requirements of the Tri-Council Policy Statement: Ethical
Conduct for
Research Involving Humans (TCPS 2); the International Conference on
Harmonisation Good Clinical Practice Consolidated Guideline (ICH GCP); Part C,
Division 5
of the Food and Drug Regulations; Part 4 of the Natural Health Products
Regulations; Part 3 of the Medical Devices Regulations and the provisions of the
Ontario
Personal Health Information Protection Act (PHIPA 2004) and its applicable
regulations. The REB is registered with the U.S. Department of Health & Human
Services
under the IRB registration number IRB 00000940.
Please do not hesitate to contact us if you have any questions.
Sincerely,
The Office of Human Research Ethics
Note: This correspondence includes an electronic signature (validation and
approval via an online system that is compliant with all regulation).
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